Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments

A technology for ischemic penumbra and salvianolic acid, which is applied in the field of preparing medicine for saving ischemic penumbra and salvianolic acid A composition, can solve the problem of low natural content, restricting drug development and research, and difficulty in separation and purification, etc. problem, to achieve the effect of simple preparation process

Active Publication Date: 2013-09-18
JIANGZI QINGFENG PHARMACEUTICALS INC
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the use of existing preparations related to cardiovascular and cerebrovascular diseases blindly pursues to increase the purity or content of salvianolic acid A in the preparation, while ignoring the attempt to explore whether the combination of salvianolic acid A and other related ingredients can achieve the same or even better effect
[0008] However, the natural content of salvianolic acid A is extremely low (about 0.01-0.06% of the salvia miltiorrhiza), which makes the cost of the original medicinal material too high, and the separation and purification are too difficult, which seriously restricts the development and research of the drug, and has become a hurdle for its industrialization. bottleneck

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments
  • Use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments
  • Use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Take Danshen medicinal material, crush it into 6-mesh granules, add 7 times the amount of 92°C water each time, warm soak and extract 3 times, and stir at a speed of 25 rpm, and warm soak and extract for 3 hours each time; the extract is concentrated under reduced pressure to relative Density 1.20 (60°C), add ethanol to make the alcohol content at 70%, let it stand, filter, the filtrate is decompressed to recover ethanol and concentrate until it has no alcohol smell; add water to dilute to contain salvianolic acid B20mg per 1ml, use 10% for aqueous solution Adjust the pH to 4.0 with sodium hydroxide, add 0.5% ZnCl 2As a catalyst, heat and transform at 120°C for 4 hours, adjust the pH value of the transformation liquid to 2.5 with 20% phosphoric acid, centrifuge, concentrate the supernatant under reduced pressure to contain 3 mg of salvianolic acid A per 1 ml, and perform HPD-100 macroporous resin column chromatography For separation, the ratio of the loading amount of s...

Embodiment 2

[0102] Take Salvia miltiorrhiza, crush it into particles with a diameter of about 2mm, add 7 times the amount of 90°C water each time, warm soak and extract 3 times, and stir at a speed of 25 rpm, and warm soak and extract for 3 hours each time; the extract is concentrated under reduced pressure to Relative density 1.17 (60°C), add ethanol to make the alcohol content 70%, stand still, filter, the filtrate recovers ethanol under reduced pressure and concentrates until it has no alcohol smell; add water to dilute to contain salvianolic acid B20mg per 1ml, and use 10 mg of salvianolic acid B in the aqueous solution Adjust the pH to 3.5 with % sodium hydroxide, add 0.5% ZnCl2 as a catalyst, heat and transform at 120°C for 4 hours, adjust the pH of the transformation solution to 2.5 with 20% phosphoric acid, centrifuge, and concentrate the supernatant under reduced pressure to contain salvianol per 1ml Salvianolic acid A 3 mg, separated by HPD-100 macroporous resin column chromatogr...

Embodiment 3

[0105] Take Salvia miltiorrhiza, cut into decoction pieces, add 8 times the amount each time, soak in water at 85°C for 3 times, stir at a speed of 20 rpm, and extract with warm soaking for 2.5 hours each time; the extract is concentrated under reduced pressure to a relative density of 1.18 (60 ℃), add ethanol to make the alcohol content at 75%, let it stand, filter, and the filtrate reclaims ethanol under reduced pressure and concentrates to no alcohol smell; add water to dilute to contain salvianolic acid B15mg per 1ml, adjust the aqueous solution with 10% potassium hydroxide pH to 5.0, add 0.6% ZnCl 2 As a catalyst, heat conversion at 120°C for 3.5 hours, adjust the pH value of the conversion liquid to 2.5 with 15% hydrochloric acid, centrifuge, concentrate the supernatant under reduced pressure to contain 5 mg of salvianolic acid A per 1 ml, pass through HPD-100 macroporous resin column layer Analysis and separation, the ratio of the loading amount of salvianolic acid A to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments. The composition is composed of danshinolic acid A, alkannic acid, rosmarinic acid, danshinolic acid B and danshinolic acid C, wherein the composition is prepared in the following weight ratios: 90-99% of danshinolic acid A, 0.1-3% of alkannic acid, 0.1-3% of rosmarinic acid, 0.1-3% of danshinolic acid B and 0.1-5% of danshinolic acid C.

Description

technical field [0001] The invention relates to the use of a salvianolic acid A composition for preparing a medicine for salvaging the ischemic penumbra. technical background [0002] Cerebrovascular disease, also known as stroke, is a neurological disease caused by various causes of blood vessels supplying the brain. The main cause is cerebral arterial lumen stenosis, vasospasm, occlusion or rupture, reduced or complete blockage of blood flow, brain blood circulation and dysfunction caused by cerebral arterial system damage (such as cerebral arteriosclerosis), and brain tissue damage. A series of symptoms caused by damage. Mainly including ischemic and hemorrhagic cerebrovascular diseases. Among them (ICVD, also known as ischemic stroke) accounted for about 80%. [0003] Ischemic cerebrovascular disease refers to the degeneration, necrosis or transient loss of function of local brain tissue including nerve cells, glial cells and connecting fibers due to blood supply dist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61K31/216A61P9/10A61P7/02A61P25/00A61P25/28A61P7/10A61P39/06C07C69/732C07C67/32
Inventor 曾发林钟阳桂蒋春红杨小玲李志勇刘地发
Owner JIANGZI QINGFENG PHARMACEUTICALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com